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SciOBJECTIVES The aim of this study was to describe current practice regarding completeness of revascularization in
patients with multivessel disease undergoing percutaneous coronary intervention (PCI) and to investigate the association
of incomplete revascularization (IR) with death, repeat revascularization, and myocardial infarction (MI) in a large
nationwide registry.
BACKGROUND The beneﬁts of multivessel PCI are controversial.
METHODS Between 2006 and 2010 we identiﬁed 23,342 patients with multivessel disease in the SCAAR (Swedish
Coronary Angiography and Angioplasty Registry) and merged data with ofﬁcial Swedish health data registries. IR was
deﬁned as any nontreated signiﬁcant (60%) stenosis in a coronary artery supplying >10% of the myocardium.
RESULTS Patients with IR (n ¼ 15,165) were older, had more extensive coronary disease, and more often had
ST-segment elevation MI at presentation than those with complete revascularization (CR) (n ¼ 8,177). All-cause 1-year
mortality, MI, and repeat revascularization were higher in IR than CR: 7.1% versus 3.8%, 10.4% versus 6.0%, and 20.5%
versus 8.5%, respectively. Propensity score methodology was used in the adjusted analyses. Adjusted hazard ratio
(HR) for the composite of death, MI, or repeat revascularization at 1 year was higher in IR than CR: 2.12 (95% conﬁdence
interval [CI]: 1.98 to 2.28; p < 0.0001). Adjusted HR for death and the combination of death/MI were 1.29 (95% CI: 1.12
to 1.49; p ¼ 0.0005) and 1.42 (95% CI: 1.30 to 1.56; p < 0.0001), respectively.
CONCLUSIONS Incomplete revascularization at the time of hospital discharge in patients with multivessel disease
undergoing PCI is associated with a high risk of recurrent 1-year adverse cardiac events. (J Am Coll Cardiol Intv
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208M ultivessel disease, that is, morethan 1 signiﬁcant coronary arterystenosis, is frequently identiﬁed
in patients with suspected or conﬁrmed
ischemic heart disease. In fact around one-
half of all patients presenting with ST-
segment elevation myocardial infarction
(STEMI) (1,2), and up to two-thirds of pa-
tients with non–ST-segment elevation acute
coronary syndrome (NSTE-ACS) have signiﬁ-
cant stenoses in more than 1 vessel (3,4).SEE PAGE 216Incomplete revascularization (IR), i.e.,
performing percutaneous coronary in-
terventions (PCI) of some but not all signiﬁ-
cant lesions, has been associated with anincreased risk for future cardiovascular events in
observational studies and subgroup analyses of ran-
domized trials (5–8). Complete revascularization (CR)
of all signiﬁcant stenoses, however, necessitates
a more complex intervention with a potentially higher
risk for complications, increases radiation exposure
and use of contrast agent, and has been associated
with worse prognosis for patients with STEMI in
some observational studies (9,10), whereas others
have suggested the opposite (11). A recent randomized
trial demonstrated a substantially reduced risk of ad-
verse cardiovascular events with multivessel PCI (12).
For patients presenting with NSTE-ACS, the Euro-
pean Society of Cardiology guidelines for revascular-
ization recommends to base the revascularization
strategy (ad hoc culprit-lesion PCI/multivessel PCI/
coronary artery bypass graft [CABG]) on the clinical
status and comorbidities as well as the disease
severity (13). For patients with stable coronary artery
disease, professional practice guidelines do not
formally address the issue of performing CR versus IR
with PCI; however, assessment of lesions with func-
tional methods such as fractional ﬂow reserve (FFR) is
recommended to avoid unnecessary treatment of
nonsigniﬁcant stenoses (14–16).
For patients presenting with STEMI, PCI of non-
culprit vessels in the acute setting is generally
discouraged in guidelines, except for patients pre-
senting with cardiogenic shock, persistent ischemia,
or in patients where electrocardiogram localization ofon advisory boards for Novartis and AstraZeneca. Dr. Varenhorst
cture fees from/served on the advisory board of AstraZeneca, Eli L
as received an institutional research grant from The Medicines
lationships relevant to the contents of this paper to disclose.
received May 27, 2015; revised manuscript received October 6, 2the infarction is ambiguous and leads to difﬁculties in
identifying the culprit lesion (13,17,18).
Because previous observational studies and small
randomized trials have yielded conﬂicting evidence
as to which strategy is superior, the evidence base for
these recommendations is rather weak.
Therefore, the aim of this study was to describe
current practice regarding completeness of revascu-
larization in a large and unselected national cohort of
patients with multivessel disease undergoing PCI, and
to investigate the association of IR with death, repeat
revascularization, and myocardial infarction (MI).
METHODS
PATIENTS. This was an observational study of pro-
spectively collected data from the SWEDEHEART
(Swedish Web-system for Enhancement and Devel-
opment of Evidence-based care in Heart disease
Evaluated According to Recommended Therapies)
and the Swedish national health data registries. The
study was approved by the Regional Ethical Review
Board in Uppsala.
The SWEDEHEART registry contains the SCAAR
(Swedish Coronary Angiography and Angioplasty
Registry) together with registries for acute cardiac
care, thoracic surgery, and secondary prevention,
forming a national quality registry prospectively col-
lecting demographic, clinical, and angiographic data
for all patients treated in every Swedish coronary care
unit and/or revascularized with PCI or CABG at every
Swedish center performing these procedures (19).
Consecutive patients with PCI performed from
January 1, 2006, to July 1, 2010, were identiﬁed in
the SWEDEHEART/SCAAR registry. Vital status, date
of death, medical and drug history, occurrence of
new myocardial infarction, and prescribed and
dispensed medications were collected from the
mandatory Swedish national health data registries:
National Cause of Death Register, National Patient
Register, and the Prescribed Drug Register. Data from
SWEDEHEART/SCAAR was merged with the Swedish
national health data registries to form a study
database.
Patients with single-vessel disease or previous
coronary bypass surgery were excluded, as well as
patients with missing data for revascularizationhas received a research grant from AstraZeneca; has
illy and Company, The Medicines Company, and St.
Company. All other authors have reported that they
015, accepted October 8, 2015.
FIGURE 1 Flow Chart of Inclusion in the Study
PCI-paƟents in SCAAR-
registry
2006 to 2010
N = 62,557
PCI-paƟents with mulƟvessel
disease
n= 23,342
Incomplete RevascularizaƟon
n = 15,165
complete RevascularizaƟon
n = 8,177
Excluded:
Previous CABG (6,003)
One vessel disease (31,046)
Missing values for Ɵme of
procedure (2,020)
RevascularizaƟon status
unknown or missing (159)
CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary intervention; SCAAR ¼
Swedish Coronary Angiography and Angioplasty Registry.
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209status and missing data for time of day (on call versus
within ofﬁce hours) for the procedure. No multiple
imputations or any other imputation method was
used, but a sensitivity analysis was done regarding
the variable for time of day (Figure 1).
The Charlson Index was used to measure comor-
bidities (20). This index includes 19 diseases that
have been selected and weighted on the basis of the
strength of their association with in-hospital and
1-year mortality (21).
PROCEDURES. Interventional strategy, lesion selec-
tion, and completeness of revascularization were at
the operators’ discretion. IR was deﬁned as any
nontreated signiﬁcant (at least 60%) stenosis in a
coronary artery supplying >10% of the myocardium
(22), on the basis of the operator’s assessment and
entered as a variable into the registry by the oper-
ator at the end of the procedure. Additional
methods to determine the signiﬁcance of lesions,
such as FFR measurements, were used at the oper-
ators’ discretion and noted in the registry. Data
regarding the procedure such as indication, angio-
graphic ﬁnding, type of procedure, stent type, stent
size, and pharmacological treatment were entered
into the registry by the operator. All Swedish PCI
centers are treating chronic total occlusions (CTOs);
however, a more dedicated and advanced CTO
treatment program that is used in some centers
today was not introduced in any of the centers
during the study period.
Patient follow-up commenced after the last PCI
that was performed during the index hospitalization.
The registry did not allow for identiﬁcation of plan-
ned staging of procedures. Therefore, we determined
revascularization status (IR or CR) after the last pro-
cedure that was performed before discharge from
hospital. Because some of the early revascularizations
after discharge may have been part of a planned
strategy of staged procedures, we performed sensi-
tivity analyses extending the time interval by 2, 4,
and 8 weeks before revascularization status was
determined.
If the patient had any drug-eluting stent (DES)
implanted during the index hospitalization they were
allocated to the DES group, whereas stents implanted
before the index hospitalization were disregarded in
the determination of DES status.
CLINICAL ENDPOINTS. The primary objective was to
describe the association of IR versus CR with the
pre-deﬁned composite endpoint of death (all cause),
MI, and repeat revascularization (PCI or CABG) up to
12 months after the initial PCI. Secondary pre-deﬁned
outcomes were the individual components of thecomposite endpoint and the combination of death
and MI during the ﬁrst 12 months.
MI was diagnosed using standard clinical criteria for
International Statistical Classiﬁcation of Diseases,
Tenth Revision codes I21-I22 collected from the
National Patient Register. Repeat PCI data were
collected from SWEDEHEART and included regardless
of whether the procedure was clinically or angio-
graphically driven. Vital status including date of death
was collected from the National Cause of Death
Registry. The Swedish personal identiﬁcation number
enables collection of outcome data for each patient;
thus, no patients were lost to follow-up.
STATISTICAL ANALYSIS. The unadjusted and
adjusted associations of IR versus CR with the com-
posite endpoint of death, MI, and repeat revasculari-
zation; the secondary composite endpoint of death/
MI; and the individual endpoint of death at 1 year were
estimated using Cox proportional hazard regression
models. For the survival analyses of the individual
endpoint of repeat revascularization, patients who
TABLE 1 Baseline Characteristics and Medical History
Incomplete
Revascularization
(n ¼ 15,165)
Complete
Revascularization
(n ¼ 8,177)
All
(N ¼ 23,342)
Baseline Characteristics
Age, yrs 68.9  11.26 66.7  10.58 68.1  11.08
Sex
Female 4,235 (27.9) 2,106 (25.8) 6,341 (27.2)
Male 10,930 (72.1) 6,071 (74.2) 17,001 (72.8)
BMI, kg/m2
n (%) 13,868 (91.4) 7,582 (92.7) 21,450 (91.9)
Mean  SD 27.0  4.32 27.3  4.29 27.1  4.31
Year of inclusion
2006 3,503 (23.1) 2,033 (24.9) 5,536 (23.7)
2007 3,296 (21.7) 1,614 (19.7) 4,910 (21)
2008 3,329 (22) 1,721 (21) 5,050 (21.6)
2009 3,267 (21.5) 1,768 (21.6) 5,035 (21.6)
2010 1,770 (11.7) 1,041 (12.7) 2,811 (12)
Creatinine clearance, ml/min
n (%) 9,481 (62.5) 6,062 (74.1) 15,543 (66.6)
Mean  SD 80.0  33.71 86.7  32.68 82.6  33.47
Medical History
Heart failure 1,012 (6.7) 378 (4.6) 1,390 (6.0)
Myocardial infarction (I21 to I22) 2,164 (14.3) 994 (12.2) 3,158 (13.5)
Peripheral vascular disease 545 (3.6) 206 (2.5) 751 (3.2)
Hypertension 8,028 (52.9) 4,364 (53.4) 12,392 (53.1)
Previous PCI 2,072 (13.7) 1,498 (18.3) 3,570 (15.3)
Atrial ﬁbrillation 1,025 (6.8) 500 (6.1) 1,525 (6.5)
Diabetes mellitus 3,220 (21.2) 1,582 (19.3) 4,802 (20.6)
Stroke 929 (6.1) 362 (4.4) 1,291 (5.5)
Renal failure 305 (2.0) 126 (1.5) 431 (1.8)
Charlson comorbidity
0 8,482 (55.9) 5,056 (61.8) 13,538 (58)
1–2 4,885 (32.2) 2,473 (30.2) 7,358 (31.5)
3–4 1,292 (8.5) 470 (5.7) 1,762 (7.5)
$5 506 (3.3) 178 (2.2) 684 (2.9)
Indication
NSTE-ACS 6,597 (43.5) 4,553 (55.7) 11,150 (47.8)
STEMI 6,143 (40.5) 1,530 (18.7) 7,673 (32.9)
Non-ACS 2,425 (16) 2,094 (25.6) 4,519 (19.4)
Values are mean  SD or n (%).
ACS ¼ acute coronary syndrome(s); BMI ¼ body mass index; NSTE-ACS ¼ non–ST-segment elevation acute
coronary syndrome; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial
infarction.
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210died during follow-up were censored. For the
analyses of death and of the composite endpoints,
patients were only censored for end of follow-up.
Because the treatment groups differed in observed
pre-treatment variables at baseline, propensity score
methodology was used in the adjusted analyses.
A multivariable logistic regression model was used to
estimate the propensity score (23). The model
included: age, sex, number of PCI procedures during
hospitalization, smoking status, indication for index
PCI (noncoronary disease, stable angina, NSTE-ACS,STEMI) cardiogenic shock at presentation, medical
history of hypertension, Charlson comorbidity index,
previous use of statins, warfarin and long-acting
nitroglycerin, number of stents placed during index
hospitalization, sum of stent length, the smallest
stent diameter, number of diseased vessels at ﬁrst
PCI, year of inclusion in registry, treating center, and
time of day (on call versus within ofﬁce hours) at
index PCI. The C-statistics for the propensity score-
model was 0.81. Proportional hazards assumption
was assessed by inspecting Schoenfeld residual plots.
To check if the propensity score assessed balance
between patients with IR and CR status for the
observed covariates, we used the Student t test and
Wald test for continuous variables and chi-square test
for proportions. The following variables were included
along with the propensity score in the adjusted Cox
regression model: mean stent diameter (index PCI),
ﬁndings (ﬁrst PCI), angiotensin-converting enzyme
inhibitors, beta-blockers, long-acting nitroglycerin
and statins at discharge, oral antidiabetics at discharge
and in medical history, heart failure and chronic
obstructive pulmonary disease in medical history,
and ﬁnally, previous PCI. As a sensitivity analysis, the
models for the primary endpoint were reanalyzed
using propensity score matching 1:1 with an 8-digit
match without replacement (24,25). A match was
found for 5,924 (39.1%) of the patients with IR status.
Student paired t test for continuous variables and
McNemar’s or Bowker’s test for proportions was used
to check if the ps-matching assessed balance between
patients with IR and CR status. Cox proportional haz-
ards models stratiﬁed on the match pairs were used
to estimate the unadjusted and adjusted associations
of IR versus CR for the primary endpoint.
For the primary endpoint, analyses were also per-
formed at 30, 90, and 180 days from the index PCI date,
as well as landmark analyses from these time points up
to day 365 after the index PCI date. These intervals
were chosen on the basis of clinically used treatment
periods for dual antiplatelet treatment (26).
Pre-speciﬁed stratiﬁed unadjusted and adjusted
analyses were also performed for ACS versus non-ACS
status at index PCI, STEMI versus NSTE-ACS, STEMI
versus stable coronary artery disease, diabetes mel-
litus versus no diabetes, treatment versus no treat-
ment with long-acting nitroglycerin, history versus
no history of MI, and/or previous PCI and any DES
versus only bare-metal stent placement at the index
hospitalization.
Because new PCI procedures during follow-up
might change the revascularization status, Cox pro-
portional hazards models with revascularization sta-
tus as a time-dependent covariate were used to
TABLE 2 Angiographic Data
Incomplete
Revascularization
(n ¼ 15,765)
Complete
Revascularization
(n ¼ 8,177)
All
(N ¼ 23,342)
Findings ﬁrst PCI
2-vessel disease 8,863 (58.4) 6,955 (85.1) 15,818 (67.8)
3-vessel disease 6,302 (41.6) 1,222 (14.9) 7,524 (32.2)
Ofﬁce hours ﬁrst PCI
Planned during ofﬁce hours 3,823 (25.2) 2,909 (35.6) 6,732 (28.8)
Emergent during ofﬁce hours 3,225 (21.3) 1,309 (16) 4,534 (19.4)
Emergent after ofﬁce hours 4,750 (31.3) 1,471 (18) 6,221 (26.7)
Urgent during ofﬁce hours 3,152 (20.8) 2,337 (28.6) 5,489 (23.5)
Urgent after ofﬁce hours 211 (1.4) 138 (1.7) 349 (1.5)
Stent type
DES 10,679 (70.4) 4,547 (55.6) 15,226 (65.2)
BMS 3,877 (25.6) 3,491 (42.7) 7,368 (31.6)
Nonstent 609 (4) 139 (1.7) 748 (3.2)
Number of stents
1 8,418 (55.5) 2,372 (29) 10,790 (46.2)
2 3,954 (26.1) 3,107 (38) 7,061 (30.3)
3 1,496 (9.9) 1,573 (19.2) 3,069 (13.1)
4–9 688 (4.5) 986 (12.1) 1,674 (7.2)
FFR index PCI 459 (3) 495 (6.1) 954 (4.1)
Values are n (%).
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); FFR ¼ fractional ﬂow reserve; NSTEMI ¼ non–ST-
segment elevation acute coronary syndrome; other abbreviations as in Table 1.
TABLE 3 Medication at Discharge
Incomplete
Revascularization
(n ¼ 15,165)
Complete
Revascularization
(n ¼ 8,177)
All
(N ¼ 23,342)
Statin 13,597 (89.7) 7,556 (92.4) 21,153 (90.6)
ACE inhibitor 11,509 (75.9) 5,843 (71.5) 17,352 (74.3)
Beta-blocker 13,354 (88.1) 7,037 (86.1) 20,391 (87.4)
Calcium-channel blocker 3,439 (22.7) 1,857 (22.7) 5,296 (22.7)
Warfarin 555 (3.7) 328 (4.0) 883 (3.8)
Aspirin 13,757 (90.7) 7,549 (92.3) 21,306 (91.3)
Clopidogrel 14,090 (92.9) 7,793 (95.3) 21,883 (93.7)
Prasugrel 48 (0.3) 24 (0.3) 72 (0.3)
Oral antidiabetic 2,097 (13.8) 1,030 (12.6) 3,127 (13.4)
Insulin 1,440 (9.5) 681 (8.3) 2,121 (9.1)
Proton pump inhibitor 4,530 (29.9) 2,232 (27.3) 6,762 (29.0)
Long-acting nitroglycerin 3,408 (22.5) 1,319 (16.1) 4,727 (20.3)
Values are n (%).
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211estimate the associations of IR with the secondary
endpoints of death and the composite of death andMI.
Secondary analyses restricted to the patients who
survived to discharge from hospital were also per-
formed. Statistical analyses were performed using
SAS version 9.3 (SAS Institute, Cary, North Carolina)
and R version 3.0.2 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
BASELINE CHARACTERISTICS, ANGIOGRAPHIC FINDINGS,
AND MEDICATION AT DISCHARGE. Of the 23,342
patients included in the study, 15,165 (65%) were
classiﬁed as IR at the index procedure. Patients in the
IR group were older, more likely to be female, more
likely to have previous cardiovascular disease, and
less likely to have undergone previous PCI compared
with the CR group. The overall comorbidity measured
with Charlson comorbidity index was higher in the IR
group than in the CR group (Table 1).
More than 1 procedure was performed in 711 cases
before discharge from hospital.
In-hospital death occurred in 571 patients: 475 in
the IR group and 96 in the CR group.
IR was performed in the majority of patients with
3-vessel disease (6,302 of 7,524; 84%), presenting
with STEMI (6,143 of 7,673; 80%), and presenting
after ofﬁce hours (4,961 of 6,570; 76%). IR patients
were more often treated with DES. FFR measure-
ments were used in 3.0% of the IR group and 6.1% of
the CR group (Table 2).
Adherence to current secondary prevention guide-
lines regarding medication was high in both IR and CR
groups. Prescription of long-acting nitroglycerin at
discharge was more common in the IR group (Table 3).
COMBINED ENDPOINT. Frequencies of the individual
endpoints are shown in Table 4. A total of 5,071
events of the primary composite endpoint (death, MI,
or repeat revascularization) occurred up to 1 year in
the IR group compared with 1,254 events in the CR
group (unadjusted HR: 2.48; 95% CI: 2.33 to 2.64;
p < 0.0001) (Figure 2). After multivariable adjustment
including the propensity score, the difference in risk
of death, myocardial infarction, or repeat revascu-
larization for the IR and CR groups remained signiﬁ-
cant: adjusted hazard ratio (HR): 2.12 (95% conﬁdence
interval [CI]: 1.98 to 2.28; p < 0.0001).
The event rate 30 days after PCI was 1,702 in the IR
group and 347 in the CR group: unadjusted HR: 2.73
(95% CI: 2.43 to 3.06; p < 0.0001), and after 90 days it
was 3,351 versus 611: unadjusted HR: 3.19 (95% CI:
2.93 to 3.48; p < 0.0001).Landmark analyses from 30 and 90 days showed
similar differences between groups: unadjusted HR
for the combined endpoint was 2.38 (95% CI: 2.21 to
2.56; p < 0.0001) and 1.78 (95% CI: 1.63 to 1.95;
p < 0.0001) for IR versus CR at 30 and 90 days.
When data was reanalyzed using propensity score
matching, consistent results were found with a
similar difference in risk of death, MI, or repeat
revascularization between the IR and CR groups:
TABLE 4 Events During 1 Year of Follow-Up
Incomplete
Revascularization
(n ¼ 15,165)
Complete
Revascularization
(n ¼ 8,177)
All
(N ¼ 23,342)
Death 1,080 (7.1) 307 (3.8) 1,387 (5.9)
Revascularization PCI 3,107 (20.5) 698 (8.5) 3,805 (16.3)
Revascularization CABG 594 (3.9) 108 (1.3) 702 (3.0)
Revascularization total 3,580 (23.6) 763 (9.3) 4,343 (18.6)
Myocardial infarction 1,570 (10.4) 492 (6.0) 2,062 (8.8)
Combined outcome of death/MI 2,470 (16.3) 754 (9.2) 3,224 (13.8)
Combined outcome of
death/MI/revascularization
5,071 (33.4) 1,254 (15.3) 6,325 (27.1)
Values are n (%).
CABG ¼ coronary artery bypass graft surgery; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention.
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212adjusted HR 2.30 (95% CI: 2.10 to 2.52; p < 0.0001)
(Online Table 1S).
SECONDARY ENDPOINTS. When we analyzed death,
with repeat revascularization as a time dependent co-
variate, the unadjusted HR for IR compared with CR
was 2.05 (95% CI: 1.80 to 2.32; p < 0.0001). For the
combined endpoint of death/MI, HR was 1.92 (95% CI:
1.77 to 2.09; p<0.0001) for IR comparedwith CR. TheseMeier Graph of the Probability of Death, MI, and
ation Up to 1 Year of Follow-Up for Patients With
complete Revascularization
50 100 150 200
Complete
Incomplete
Days
250 300 365
7734 7529 7349 7118 6752 6425 6003
12670 11658 11093 10598 9941 9427 8797
rction.differences remained statistically signiﬁcant after
adjustment: HR: 1.29 (95% CI: 1.12 to 1.49; p ¼ 0.0005)
for death and HR: 1.42 (95% CI: 1.30 to 1.56; p< 0.0001)
for the combination of death/MI.
A signiﬁcantly higher hazard for IR compared with
CR patients was consistent across all subgroups
(Table 5).
When we prolonged the time interval to 2, 4, or 8
weeks to determine revascularization status of the
study patients, the magnitude of effect size for the
combined endpoint was similar (Online Tables 2S to 4S).
However, when we analyzed death up to 1 year
only in patients surviving to discharge, the differ-
ences in HR between the IR and CR groups did not
remain in all subgroups (Table 6).
DISCUSSION
In this nationwide, observational, registry-based
study of all Swedish PCI patients with multivessel
disease treated in 2006 to 2010, we observed a high
event rate associated with IR after PCI. Death or MI
occurred in 17% of patients with IR and an additional
20% required repeat revascularization. Compared
with CR, IR was associated with substantially higher
event rates after discharge.
After multivariable adjustment including pro-
pensity score analysis, patients IR experienced a
2-fold risk for the composite of death, MI, or repeat
revascularization at 1 year compared with patients
with CR. Because the decision to perform repeat
revascularization could be biased due to the knowl-
edge of remaining signiﬁcant stenoses, we also
investigated differences in outcome leaving out
repeat revascularization. The differences persisted
with approximately the same magnitude regarding
the individual components of death and MI. To
reduce the effect of possible planned staged pro-
cedures, we also performed landmark studies at
different time points with consistent ﬁndings.
The anatomical disease burden, that is, number of
diseased vessels, is of prognostic value in patients
with stable angina (27) and in NSTE-ACS patients
treated with early invasive strategy and contempo-
rary adjunctive antithrombotic and anticoagulant
therapy (28). The negative effect of multivessel
disease on prognosis compared with single-vessel
disease was, however, not demonstrated in STEMI
patients in a recent observational study (29).
The effect of performing CR on mortality, repeat
revascularization, and MI has been investigated only
in a few small prospective randomized trials. In a
single-center study, 219 patients without ongoing MI
were randomized to PCI of the culprit vessel only
TABLE 5 Unadjusted and Adjusted Hazard Ratio for Stratiﬁed Analyses of
Incomplete Versus Complete Revascularization on the Outcome of Death, MI,
and Repeat Revascularization With 1 Year of Follow-Up
Unadjusted HR p Value Adjusted HR p Value
All patients 2.48 (2.33–2.64) <0.0001 2.12 (1.98–2.28) <0.0001
STEMI 2.19 (1.95–2.46) <0.0001 2.03 (1.79–2.30) <0.0001
NSTE-ACS 2.17 (1.99–2.37) <0.0001 2.02 (1.83–2.23) <0.0001
Stable CAD 2.66 (2.28–3.11) <0.0001 2.59 (2.18–3.08) <0.0001
Diabetes 2.13 (1.87–2.41) <0.0001 1.85 (1.60–2.13) <0.0001
Nitroglycerin treatment 1.99 (1.71–2.32) <0.0001 1.62 (1.36–1.93) <0.0001
Previous MI and/or PCI 1.94 (1.71–2.20) <0.0001 1.59 (1.38–1.83) <0.0001
DES (any) 2.51 (2.26–2.80) <0.0001 2.10 (1.86–2.37) <0.0001
BMS (only) 2.33 (2.16–2.52) <0.0001 2.11 (1.93–2.30) <0.0001
Values are hazard ratio (HR) (95% conﬁdence interval). Index PCI date is day 0 (N ¼ 23,342).
CAD ¼ coronary artery disease; MI ¼ myocardial infarction; other abbreviations as in
Tables 1 and 2.
TABLE 6 Unadjusted and Adjusted Hazard Ratio for Stratiﬁed Analyses of
Incomplete Versus Complete Revascularization on the Outcome of Death With
1 Year of Follow-Up
Unadjusted HR p Value Adjusted HR p Value
All patients 1.77 (1.52–2.06) <0.0001 1.24 (1.05–1.48) 0.0127
STEMI 1.41 (1.08–1.84) 0.0116 1.06 (0.80–1.41) 0.6867
NSTE-ACS 1.91 (1.54–2.37) <0.0001 1.38 (1.08–1.76) 0.0112
Stable CAD 1.63 (1.07–2.48) 0.0217 1.27 (0.79–2.03) 0.3296
Diabetes 1.68 (1.28–2.19) 0.0002 1.40 (1.03–1.90) 0.0331
Nitroglycerin treatment 1.66 (1.22–2.27) 0.0013 1.04 (0.73–1.49) 0.8297
Previous MI and/or PCI 1.67 (1.28–2.17) 0.0002 0.94 (0.70–1.27) 0.6885
DES (any) 1.49 (1.11–1.98) 0.0070 1.03 (0.75–1.43) 0.8463
BMS (only) 1.74 (1.44–2.10) <0.0001 1.30 (1.05–1.60) 0.0152
Values are hazard ratio (HR) (95% conﬁdence interval). Repeat revascularization is analyzed as a
time-dependent variable. Only patients surviving to discharge from hospital are included in this
analysis (n ¼ 22,771).
Abbreviations as in Tables 1, 2, and 4.
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213versus CR, resulting in lower strategy success rate
and higher procedural costs for the CR group, but
similar in-hospital and 1-year major adverse cardiac
event rates (30). The PRAMI (Preventive Angioplasty
In Myocardial Infarction) trial, which randomized
465 patients with STEMI to PCI of infarct-related
coronary artery only or CR in the same setting,
demonstrated reduced risk of adverse cardiovascular
events with multivessel PCI after a median follow-up
of 23 months (12). The open-label design, small
number of events, and large number of patients lost
to follow-up limited the interpretability of this trial.
Nonetheless, the results of the PRAMI trial are in
line with the conclusions in a recent meta-analysis
of 3 randomized and 23 nonrandomized studies
investigating culprit-only versus multivessel PCI in
STEMI patients, where multivessel PCI was associ-
ated with improved long-term survival and reduced
repeat PCI. There was, however, an increase in
in-hospital mortality when multivessel PCI was per-
formed during the index primary PCI procedure,
which was not seen with a staged procedure (31).
When we analyzed the subgroup of STEMI patients
in our study, we did not ﬁnd a signiﬁcant difference
in risk of death after hospital discharge up to 12
months between the IR and CR groups. However, for
the composite of death, MI, or repeat revasculariza-
tion, STEMI patients reﬂected the results of the
overall study with an adjusted HR of 2 for the IR
group compared with the CR group at 12 months.
The results in our study were also consistent with
another recent meta-analysis excluding STEMI
studies but including studies where revascularization
was performed with CABG or PCI, in which the au-
thors found an association between CR and lower risk
for death, MI, and repeat revascularization (32).
In addition to survival and repeat procedures,
health-related quality of life is an important
outcome. For elderly patients and patients with
comorbidities and a shorter expected remaining life
span, this may be perceived as even more important
than a reduction in event rates. In this study, we did
not speciﬁcally capture measures of quality of life or
disease burden. However, treatment with long-acting
nitroglycerin likely reﬂects symptoms of angina pec-
toris, and we did observe that long-acting nitroglyc-
erin use was more common in the IR group. In
contrast, a previous study suggested that selective
revascularization can lead to acceptable results for
patients above the age of 75 years (33).
STUDY LIMITATIONS. Despite its size and national
scope, this observational study has inherent limita-
tions. First, the issue of unmeasured confoundersmust always be considered when interpreting results
of nonrandomized studies. The basic assumption for
the propensity score methodology is that there are no
unmeasured confounders that inﬂuence treatment
assignment and outcome, and this can never be
achieved in any observational study. In the absence
of clear guideline recommendations, the decision to
perform complete rather than more limited revascu-
larization is likely on the basis of the patient’s char-
acteristics and preferences together with the
knowledge and experience of the operator, the
appearance of the coronary vessels, and the technical
complexity of the lesions. The granular details of
these factors cannot be completely captured in this
registry despite taking many other potentially con-
founding variables into account.
Second, some of the lesions not being revascular-
ized may have been CTOs that may or may not have
PERSPECTIVES
WHAT IS KNOWN? There is conﬂicting evidence
regarding CR versus IR in patients with multivessel
disease undergoing PCI.
WHAT IS NEW? Our observational study showed
that IR at the time of hospital discharge was associ-
ated with a high risk of 1-year mortality, MI, or repeat
revascularization.
WHAT IS NEXT? Whether this high risk can be
reduced by a strategy of CR needs to be further
investigated in a randomized trial.
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214been technically addressable by PCI. Presence of CTO
in a noninfarct-related artery has been demonstrated
to be an indicator of mortality (1), whereas successful
CTO PCI has been associated with lower mortality in
patients in stable condition and a small study with
STEMI patients (34,35).
Third, the use of FFR measurement as an addi-
tional method to evaluate which stenoses were
functionally signiﬁcant, as opposed to relying on
anatomical estimation, was used in only a minority of
patients. Increased use of FFR measurement in non-
STEMI ACS patients and patients in stable condition
has the potential to reclassify patients regarding
number of diseased vessels and has been shown to
improve outcome (36).
Because our study is observational, the question of
whether the higher event rates in incompletely reva-
scularized patients can be lowered with a treatment
strategy aiming at full revascularization still remains
unclear and cannot be answered in a registry study.
CONCLUSIONS
For patients with multivessel disease undergoing
PCI, IR achieved at the time of hospital discharge was
associated with a high risk of death, repeatrevascularization, or MI in the ﬁrst year. Whether this
risk can be mitigated by efforts to achieve CR, or by
the use of novel adjunctive pharmacological strate-
gies, remains to be further investigated in large ran-
domized trials.
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